Fan to prevent ticagrelor-related shortness of breath
Part of Heart & circulation, Lungs & breathing clinical trials.
This study tests whether using a small fan can help reduce the shortness of breath (dyspnea) that some people feel when they first start taking the blood thinner ticagrelor after a heart attack.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- This is your first time having a heart attack or unstable angina, and you are about to start the blood thinner ticagrelor.
- You do not have any lung disease (like asthma, COPD, or lung cancer) or sleep apnea.
- You can speak and understand Turkish and have no major hearing or vision problems.
- You are willing and able to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking a single blood-thinning medication (instead of two) after heart stent placement is safe and effective over the long term. If you've recovered well from a stent procedure, this trial may help determine the safest way to prevent future heart problems.
This study tests whether taking dabigatran (a blood thinner) combined with ticagrelor (a blood clot preventer) is safe and effective for patients with irregular heart rhythm (atrial fibrillation) who recently had a heart attack and received a stent. The goal is to prevent future blood clots while minimizing bleeding risks.
This study tests if a single blood thinner (ticagrelor) works well enough after getting a heart stent, instead of the usual two blood thinners. It may simplify your daily medication routine.
This trial tests whether taking ticagrelor (a blood thinner) alone, without aspirin, is safe and effective for people who have had a heart attack and are being treated with medication only (no stents or bypass surgery). It could mean fewer pills and possibly reduce bleeding risks.
This trial tests a shorter course of dual antiplatelet therapy (aspirin plus ticagrelor) after stent placement, switching early to just ticagrelor alone. It aims to see if this approach can safely reduce bleeding risks while still protecting against heart problems in people with stable coronary artery disease.
This study compares ticagrelor taken at a lower dose versus regular aspirin to help prevent future heart attacks in people who recently had a stent placed after acute coronary syndrome. You may qualify if you’re considered “high risk” for new blockages or clots and can take dual anti-platelet therapy for 12 months.
Hear when a new Ticagrelor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.